Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer
Tumor size, nodal involvement, and histologic subtype are key prognostic determinants in stage II NSCLC. Identifying high-risk patients is crucial to optimize selection for adjuvant immunotherapy or targeted therapy and to ensure clinical and economic benefit.
Authors
- Tai-Huang Lee
- C. Y. Yang
- Y Li
- S.W. Kao
- Jui-Ying Lee
- Yu-Ting Lo
- Hui-Yang Hung
- CHIA-HUA LIU
- YU-WEI LIU
- YI-WEN SHEN
- WEI-AN LAI
Institutions
- Kaohsiung Medical University (TW)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18005
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00